StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

BioXcel Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -6054.7%. For fiscal 2025 it was -7860.0%, against -2967.6% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-7860.0%−4892.4
FY2024Dec 31, 2024-2967.6%+9480.4
FY2023Dec 31, 2023-12448.0%+30124.0
FY2022Dec 31, 2022-42572.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-5600.5%+7609.5
Q1 FY2026Mar 31, 2026-4962.6%+1048.7
Q4 FY2025Dec 31, 2025-4016.4%−1149.5
Q3 FY2025Sep 30, 2025-14518.4%−7372.1
Q2 FY2025Jun 30, 2025-13210.0%−11643.3
Q1 FY2025Mar 31, 2025-6011.3%−1859.6
Q4 FY2024Dec 31, 2024-2866.9%+2419.0
Q3 FY2024Sep 30, 2024-7146.3%+7017.1
Q2 FY2024Jun 30, 2024-1566.7%+9902.5
Q1 FY2024Mar 31, 2024-4151.7%+20701.7
Q4 FY2023Dec 31, 2023-5285.9%+16938.5
Q3 FY2023Sep 30, 2023-14163.3%+14296.5
Q2 FY2023Jun 30, 2023-11469.1%–
Q1 FY2023Mar 31, 2023-24853.4%–
Q4 FY2022Dec 31, 2022-22224.4%–
Q3 FY2022Sep 30, 2022-28459.9%–

More BioXcel Therapeutics figures

See a number that looks wrong?